Overview

A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis

Status:
NOT_YET_RECRUITING
Trial end date:
2031-03-31
Target enrollment:
Participant gender:
Summary
This Phase III, randomized, double-blind, multicenter, induction and maintenance study will evaluate the safety and efficacy of Afimkibart (RO7790121) in pediatric participants with moderate to severe active ulcerative colitis (UC).
Phase:
PHASE3
Details
Lead Sponsor:
Hoffmann-La Roche